Current methods of diagnosis and treatment of neuropsychiatric disorders in systemic lupus erythematosus DOI

A. N. Pernebay,

Asem M. Orynbaeva,

B. K. Makhmutova

et al.

Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery), Journal Year: 2024, Volume and Issue: 10, P. 1196 - 1208

Published: Oct. 17, 2024

Neuropsychiatric systemic lupus erythematosus (NPSLE) is a severe complication of (SLE), characterized by damage to the nervous system. The article discusses pathogenesis, clinical manifestations, laboratory and instrumental diagnostics, as well modern promising methods treating NPSLE. Both immunoinflammatory (autoantibodies, cytokines) ischemic (thrombosis, vasculitis) mechanisms are involved in NPSLE pathogenesis. picture varied includes cognitive impairment, headache, seizures, psychosis, other neurological psychiatric symptoms. Diagnosis difficult due lack specific biomarkers. markers (antibodies dsDNA, Sm, SSA/Ro, SSB/La, aPL, anti-P, complement components) system-specific NR2, U1RNP, GAPDH, S100B, NfL, cytokines CSF) used. Instrumental diagnostics incorporates MRI, fMRI, MRS, DTI, PET, SPECT. Treatment glucocorticoids, immunosuppressants, anticoagulants, symptomatic therapy. Promising treatments include inhibitors, BBB repair therapies, MMPs IFN-α/β receptor antagonists, BTK S1P modulators, ACE CSF1R Nogo-A/NgR1 antagonists.

Language: Английский

Challenges of anticoagulation in patients with systemic lupus erythematosus DOI
Luigi Zolio, Hannah Cohen,

David Isenberg

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 20, 2025

Anticoagulation is frequently required for patients with systemic lupus erythematosus (SLE), given their high prevalence of cardiovascular disease and thrombosis, due to the complexity pathophysiology, some overlap antiphospholipid syndrome (APS), comorbidities, prevalent risk factors treatment complications. This article outlines epidemiology pathophysiology arterial and/or venous thrombosis in SLE, with/without APS. We discuss common comorbidities thrombotic disorders that may present as a complication SLE APS highlight recommendations current guidelines anticoagulation management, alongside relevant disease-specific considerations. specifically comment on use direct oral anticoagulants (DOACs) thromboembolism(VTE) these patients. Assessment aPL profile paramount While warfarin preferred high-risk patients, DOACs can be used selected group VTE no prior history thrombosis. Initiating setting Catastrophic (CAPS) extremely challenging. Knowledge gaps remain regarding management recurrent despite anticoagulation. Research needed optimize strategies reduce events

Language: Английский

Citations

0
Perfusion-weighted MRI patterns in neuropsychiatric systemic lupus erythematosus: a systematic review and meta-analysis DOI
Narges Azizi, Mahbod Issaiy,

Amir Hossein Jalali

et al.

Neuroradiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 4, 2024

Language: Английский

Citations

2
From Multimorbidity to Network Medicine in Patients with Rheumatic Diseases DOI Creative Commons
Winston Gilcrease, Luca Manfredi, Savino Sciascia

et al.

Rheumatology and Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 27, 2024

The transition from a comorbidity-based to multimorbidity-focused ultimately network medicine approach in people with rheumatic diseases might mark significant shift how we understand and manage these complex conditions. Multimorbidity expands on the concept of comorbidity by encompassing presence multiple diseases, which results further individual societal impacts. This approach, while valuable, often leads fragmented care focused rather than patient as whole. Network medicine, other hand, offers more integrated perspective. It is an emerging that leverages understanding biologic networks their interactions within human body gain insights into disease mechanisms. In context involves examining different interconnect influence each through shared pathways, genetic factors, molecular paradigm allows for holistic diseases. For instance, such rheumatoid arthritis systemic lupus erythematosus are not just collection symptoms affecting various organs but also interconnected underlying inflammatory processes, immune system dysregulation, predispositions.

Language: Английский

Citations

2
Advancements in Immunology and Microbiology Research: A Comprehensive Exploration of Key Areas DOI Creative Commons
Angel A Justiz-Vaillant, Darren Gopaul,

Sachin Soodeen

et al.

Microorganisms, Journal Year: 2024, Volume and Issue: 12(8), P. 1672 - 1672

Published: Aug. 14, 2024

Immunology and microbiology research has witnessed remarkable growth innovation globally, playing a pivotal role in advancing our understanding of immune mechanisms, disease pathogenesis, therapeutic interventions. This manuscript presents comprehensive exploration the key areas immunology research, spanning from utilisation bacterial proteins as antibody reagents to intricate realms clinical management. The immunoglobulin-binding (IBPs), including protein A (SpA), G (SpG), L (SpL), revolutionised serological diagnostics, showing promise early detection precision medicine. Microbiological studies have shed light on antimicrobial resistance patterns, particularly emergence extended-spectrum beta-lactamases (ESBLs), guiding stewardship programmes informing strategies. Clinical elucidated molecular pathways underlying immune-mediated disorders, resulting tailored management strategies for conditions such severe combined immunodeficiency (SCID), neuropsychiatric systemic lupus erythematosus (NPSLE), etc. Additionally, significant efforts vaccine development against tuberculosis HIV are highlighted, underscoring ongoing global pursuit effective preventive measures these infectious diseases. In summary, provided contributions healthcare, fostering collaboration, innovation, improved patient outcomes.

Language: Английский

Citations

1
Clinical, immunological and neuroimaging spectrum of CNS lupus: can we reliably differentiate it from MS? DOI Creative Commons
Anna Wójcicka-Frankiewicz, Mikołaj A. Pawlak, Alicja Kalinowska-Łyszczarz

et al.

Neurologia i Neurochirurgia Polska, Journal Year: 2024, Volume and Issue: 58(6), P. 557 - 568

Published: Dec. 27, 2024

Language: Английский

Citations

0
Current methods of diagnosis and treatment of neuropsychiatric disorders in systemic lupus erythematosus DOI

A. N. Pernebay,

Asem M. Orynbaeva,

B. K. Makhmutova

et al.

Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery), Journal Year: 2024, Volume and Issue: 10, P. 1196 - 1208

Published: Oct. 17, 2024

Neuropsychiatric systemic lupus erythematosus (NPSLE) is a severe complication of (SLE), characterized by damage to the nervous system. The article discusses pathogenesis, clinical manifestations, laboratory and instrumental diagnostics, as well modern promising methods treating NPSLE. Both immunoinflammatory (autoantibodies, cytokines) ischemic (thrombosis, vasculitis) mechanisms are involved in NPSLE pathogenesis. picture varied includes cognitive impairment, headache, seizures, psychosis, other neurological psychiatric symptoms. Diagnosis difficult due lack specific biomarkers. markers (antibodies dsDNA, Sm, SSA/Ro, SSB/La, aPL, anti-P, complement components) system-specific NR2, U1RNP, GAPDH, S100B, NfL, cytokines CSF) used. Instrumental diagnostics incorporates MRI, fMRI, MRS, DTI, PET, SPECT. Treatment glucocorticoids, immunosuppressants, anticoagulants, symptomatic therapy. Promising treatments include inhibitors, BBB repair therapies, MMPs IFN-α/β receptor antagonists, BTK S1P modulators, ACE CSF1R Nogo-A/NgR1 antagonists.

Language: Английский

Citations

0